Data from a pooled analysis published in the journal Cancer recently, shows that stereotactic ablative radiotherapy (SABR) can effectively treat patients with primary renal cell carcinoma (RCC), whilst preserving renal function.
In this study, data from 233 people with RCC who had undergone SABR treatment were pooled; 118 patients received single-fraction SABR and 105 received multi-fraction SABR. There were excellent rates of local control (97.8%), cancer-specific survival (95.7%), and progression-free survival (77.4%) at 2 years. At 4 years, these rates were mostly maintained at 97.8%, 91.9%, and 65.4%, respectively. The analysis showed that larger tumours and multi-fraction SABR were associated with poorer progression-free survival and cancer-specific survival.
Overall, the SABR treatment was well tolerated, and there was also good preservation of renal function after SABR in this study.
“Local control, minimal complications, and preserved renal function are considered to constitute ‘the trifecta’ after minimally invasive partial nephrectomy,” the researchers wrote. “The current multi-institutional, pooled analysis marks an important step in demonstrating that SABR can achieve this trifecta in localised RCC.”